WINNIPEG, Manitoba, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSXV:KNE) (the "Company", "Kane" or "Kane Biotech") announces that today it has completed its previously announced non-brokered private placement offering (the "Offering") of common shares of the Company ("Shares").At the closing of the Offering, Kane issued 14,000,000 Shares at a price of $0.05 per Share for gross proceeds of $700,000 to an insider of the Company.The net proceeds of the Offering will be used for working capital and ge ...

Core Points - Kane Biotech Inc. has completed a non-brokered private placement offering of common shares, issuing 14,000,000 shares at a price of $0.05 per share, resulting in gross proceeds of $700,000 [2] - The net proceeds from the offering will be allocated for working capital and general corporate purposes [2] - The transaction is classified as a "related party transaction" under Multilateral Instrument 61-101, and the company is exempt from formal valuation and minority approval requirements [3] Company Overview - Kane Biotech is focused on developing innovative wound care treatments that target biofilms, which contribute to antibiotic resistance in wounds, leading to serious clinical outcomes and high costs [5] - The company's products, including revyve® Antimicrobial Wound Gel and revyve® Antimicrobial Wound Gel Spray, have received US FDA 510(k) clearance and Health Canada approval [5]

WINNIPEG, Manitoba, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announced its third quarter 2025 financial results. Third Quarter 2025 Financial Highlights (Comparatives exclude discontinued STEM Animal Health “STEM” Operations): Total revenue for the three months ended September 30, 2025 was $8,499 compared to $1,282,698 in the three months ended September 30, 2024. The vast majority of revenue recorded in the comparative quarter was relat ...

Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces its intention to undertake a non-brokered private placement offering (the “Offering”) of up to 16 million common shares (“Shares”) at a price of $0.05 per Share for gross proceeds of up to $800,000. The net proceeds of the Offering will be used for working capital and general corpora ...

Core Insights - Kane Biotech Inc. has completed a U.S. FDA 510(k) clearance submission for its revyve Antimicrobial Wound Cleanser, marking a significant step in its product development [1][2] Product Development - The revyve Antimicrobial Wound Cleanser is the third product in the revyve line, complementing the existing revyve Antimicrobial Wound Gel and Antimicrobial Wound Gel Spray [2] - This new product aims to enhance routine wound management by providing irrigation to cleanse both acute and chronic wounds, thereby reducing bacterial load and removing debris [2] Market Opportunity - The annual U.S. market size for wound cleansers surpassed $200 million USD in 2024, indicating a substantial market opportunity for Kane Biotech's new product [3]

Financial Performance - Total revenue for Q2 2025 was $27,997, a significant decrease from $620,437 in Q2 2024, primarily due to the sale of the animal health business [9] - Gross loss for Q2 2025 was $(45,526), compared to a gross profit of $360,490 in Q2 2024 [9] - Total operating expenses for Q2 2025 were $229,930, down from $1,463,397 in Q2 2024, attributed to staff reductions and other cost-saving measures [9] - Net loss for Q2 2025 was $(348,541), an improvement from a net loss of $(1,215,996) in Q2 2024 [9] Corporate Governance - Three new directors were elected at the Annual and Special Meeting of Shareholders on June 25, 2025, alongside the reelection of three existing directors [2] - Mr. Shameze Rampertab was appointed as Chair of the Audit and Compensation Committee, and Ms. Anne Greven as Chair of the Governance & Nomination Committee [3] Product Development and Clinical Engagement - Kane Biotech presented novel preclinical data and clinical observations at two major North American wound care conferences in 2025 [4] - The company is engaging with key wound care specialists in the U.S. and is completing a clinical case series program to generate additional clinical data [5] Distribution and Financial Obligations - The company terminated its exclusive distribution agreement with ProgenaCare due to material breaches and is in discussions with potential new distributors [6] - Kane Biotech received a notice of default from Prairies Economic Development Canada regarding approximately $1.4 million outstanding from a $2.5 million Contribution Agreement [8] Strategic Outlook - The company aims to enhance its distributor networks in the U.S. and is focused on generating compelling clinical evidence to support the commercialization of its revyve portfolio [10] - The addition of three qualified directors is expected to strengthen the company's strategic capabilities during a pivotal growth stage [10]

Group 1 - Kane Biotech Inc. has completed a non-brokered private placement offering, issuing 12,000,000 common shares at a price of $0.10 per share, resulting in gross proceeds of $1,200,000 [2] - The net proceeds from the offering will be utilized for working capital and general corporate purposes [2] - The company has also secured an unsecured loan of $1,000,000 from an insider, which is interest-free and repayable on demand [3] Group 2 - The transactions are classified as "related party transactions" under Multilateral Instrument 61-101, with the company exempt from formal valuation and minority approval requirements [4] - Kane Biotech is focused on developing innovative wound care treatments that target biofilms, which contribute to antibiotic resistance and complicate wound healing [6]